🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Felipe K. Hurtado

ORCID: 0000-0002-5254-972X

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer”.

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2742

N/A

1.8DataRank · unranked

70 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa +13 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020.v1

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more